Tag Archives: liver metastases

Colorectal Cancer News in Brief: July 10

Research this week finds FDG/PET able to predict response to chemotherapy even after one treatment, and chemotherapy before surgery for liver mets makes CT scan evaluation less accurate. Finding the best imaging methods to diagnosis and monitor cancer and comparing new colorectal cancer screening technologies to current standards are among recommended priorities for comparative effectiveness research (CER).  The FDA reports new egg safety rules and the recall of a powdered dietary supplement. Videos of cancer patients are now online discussing the emotional impact of their diagnosis in The Day I Found Out.

Colorectal Cancer News in Brief: July 7

News in Brief catches up today after celebrating the Fourth of July with swimming, sailing, and time with family.  We hope you had as good a time relaxing as we did. Research shows that children whose parents have cancer have more social and psychological problems, mice who are fed a high-fat Western-style diet don’t benefit from exercise and develop more colon polyps, and adding irinotecan to 5FU after surgery to remove liver mets adds no benefit but has more serious side effects. The VA is upgrading equipment to sterilize endoscopes and train staff to clean them properly with $26 million from its reserve funds.  Two scientists at MIT are sampling

Hepatic Perfusion Treatment Improves Survival and Shrinks CRC Liver Tumors

Colorectal cancer patients whose cancer had spread to their livers benefited from surgery during which heated chemotherapy was pumped directly to their livers. Isolated hepatic perfusion (IHP) shrank tumors and increased survival time.  It may be a hopeful new approach to treating colorectal cancer that is widespread in the liver. Median survival time after the treatment was a little over 17 months.  A third of patients lived two years or more. A clinical trial of a similar hepatic perfusion technique without open surgery is currently available at the NIH Clinical Center in Bethesda, Maryland.

Response to Chemo Before Liver Met Resection Doesn't Predict Survival

Patients who had tumors shrink in response to chemotherapy given before they had surgery for colorectal cancer that had spread to their livers had no better long-term survival than patients whose cancer remained the same or even got worse. Doctors in New York followed 111 patients who had chemotherapy before surgery to remove liver metastases (neoadjuvant chemotherapy). After five years of follow-up, median overall survival was 62 months.  Overall survival was similar in three different groups:  those who had a complete or partial response to neoadjuvant chemotherapy, those whose tumors remained stable, and those whose cancer progressed during chemotherapy.

Liver Symposium Brings Survivors and Health Pros Together

The Liver Symposium will bring together patients and health care providers at the Palmer House in Chicago on May 15 and 16 in a unique collaboration of contining medical education and cancer survivor input to share the latest information about managing liver tumors. Sponsored by YES, a grassroots organization of liver tumor survivors dedicated to helping patients learn their options, the Symposium will provide both supportive survivor-led sessions and presentations from medical experts. Jim Belushi and the Sacred Hearts will perform at a special welcome dinner for survivors on Thursday evening at 7:30. Scholarship help is available for survivors and patients to attend.  Contact Suzanne Lindley for more information or call

Stereotactic Body Radiotherapy for Liver Mets Safe

An early clinical trial of focused radiation therapy for liver metastases appeared to be safe without causing liver disease. Stereotactic body radiotherapy (SBRT) delivers high doses of radiation to a carefully targeted area of the body.  Its goal is to destroy cancer cells while leaving healthy tissue unharmed. Radiation oncologists at Princesss Margaret Hospital at the University of Toronto used SBRT to treat 68 patients with cancer that had spread to their liver, 40 of whom had colorectal cancer.  Patients, who were not eligible for surgery or additional chemotherapy, had six radiotherapy treatments over two weeks.

Survival of Medicare Patients after Surgery for Liver Mets

While some surgical studies are now reporting five-year survival after surgery to remove colorectal cancer tumors that have spread to the liver of 40 to 60 percent, a review of more general national experience for patients enrolled in Medicare  in the United States found lower survival rates. Among Medicare-enrolled colorectal cancer patients 65 and over who had liver resection, only 26 percent (1 in 4) were alive five years later.

Surgery or RFA for Liver Mets?

Both surgery and radiofrequency ablation (RFA) are used to destroy liver tumors that have spread from colorectal cancer, but which approach is better? Surgeons at the University of Louisville School of Medicine reviewed all the cases where patients received either surgery only or RFA only in their hospital over the past twelve years.  They had over 1,100 cases involving liver tumors during that time, and 192 involved either a single liver surgery or only radiofrequency ablation. They found the time before cancer came back was considerably shorter for RFA.  In addition, cancer returned at the RFA or surgical site more often for RFA, and also recurred more often elsewhere in

Improved Outcomes with Chemotherapy After Surgery to Remove Metastases

Patients who received chemotherapy after surgery to remove colorectal cancer that had spread to their liver or lungs had better long-term outcomes than those who only had surgery, according to an analysis that pooled two similar studies. Two different clinical trials studied chemotherapy after surgical removal of liver or lung metastases due to colorectal cancer.  While neither trial was large enough to draw clear conclusions on its own, researchers combined information from both to decide if chemo made a difference for patients.